The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Off we go again?
Last orders @ 26.5p by the looks!
Last orders @ 26.5p by the looks!
Sp going back up to 29.5p???????
It seems!
The sp here up 4% plus I believe.
We shall see!!!
Up 1.28%
so one would think CCL will have a very good day...........
Up 1.2%
so one would think CCL will have a very good day...........
Up 13.41%. Nice.
Current sp to have any chance of succeeding IMHO. As you point out with further funding there is no reason why the Parsortix technology could not get FDA clearance for medical use with cancers other than breast thus increasing the available market by something like 90%. I hasten to add the existing Breast cancer market combilned with the enourmous cancer drug trials markets should be easily enough for Angle Plc as it stands. To get a bid Angle need a decent sized pharma Co. to realise the potential here.
All IMHO.
Gawdhelpus !
MM's back on the ball. Bid 19p/ask 20p. Don't see them offering the same price for both very often........ LOL!
Something big happening????
Trials by using Angle's Parsortix machine to catch the circulating tumour cells for testing. Potentially there may also be a massive market for testing the patients circulating tumour cells to see if they are suitable for the Immunotherapy treatment in the first place.
https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors
All IMHO.
Up 4%.
TwoGood2Die. Clearly you did not look at the presentation (see link below). You really need to stop posting complete and utter rubbish on this bb and actually look at the presentations. Then you might post something that is actually true and is based on fact not complete fiction>>:-
The research side enables the monitoring of both HER2 and PD-L1 proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.
https://www.youtube.com/watch?v=cnQ6M05BiBY
https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/
Reply
Up 4%.
large trade to appear later.
Probably!
Proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.
https://www.youtube.com/watch?v=cnQ6M05BiBY
https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/
To me this discussion is fairly unimportant. Angle have FDA approval for hospitals using the Parsortix machine to catch circulating tumour cells (CTC's) from a blood sample from someone with metastasized breast cancer to get the HER2 status of the cancer etc.......... That market World wide is more than enough on it's own. I'm far more interested in the last announcement which basically says the partnership with Bioview to develop an automated CTC HER2 assay which uses A.I. is coming along nicely. PD-L1 to follow looks logical does it not............................................................?
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
So it's only down 0.56% in the last 5 days, as you have posted.
Not as bad as it might look today then.
Similar the the HER2 one but targeting PD-L1 evaluation........................
That would cover most of the Immunotherapy drugs available that are all over the news.
And the sp is down!